CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(04): 151-152
DOI: 10.4103/0971-5851.65344

Intestinal mantle cell lymphoma recurring at laparotomy scar region

Amitabh Ray
Department of Radiation Oncology, AMRI Hospitals, India
Ayan Basu
Department of Radiation Oncology, AMRI Hospitals, India
Jyotirup Goswami
Department of Radiation Oncology, AMRI Hospitals, India
Kalyan Bhattacharya
Department of Radiation Oncology, AMRI Hospitals, India
› Author Affiliations


Mantle cell lymphoma (MCL) is a moderately aggressive variety of non-Hodgkins lymphoma. Extranodal presentation of MCL is well known, the intestine being a common site. The incidence of colorectal involvement is relatively rare. Moreover, the recurrence of the disease at laparotomy scar site is even more rare. We report an unusual case of incision line recurrence in a case of colonic MCL occuring three years after initial treatment.

Publication History

Article published online:
19 November 2021

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Meral M, Demirpenηe M, Gφnen C, Akarsu M, Kayahan H, Demirkan F, et al. Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol 2008;19:117-20.
  • 2 Lorenz U, Gassel AM, Thiede A, Gassel HJ. Endometrial carcinoma recurrence in an abdominal scar 14 years after total hysterectomy. Gynecol Oncol 2004;95:393-5.
  • 3 Amer MH, el-Akkad S. Gastrointestinal lymphoma in adults: Clinical features and management of 300 cases. Gastroenterology 1994;106:846-58.
  • 4 Weisenburger DD, Armitage JO. Mantle cell lymphoma: An entity comes of age. Blood 1996;87:4483-94.
  • 5 Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
  • 6 Hiddemann W, Dreyling M, Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003;30:16-20.
  • 7 Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867.
  • 8 Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in refractory mantle cell lymphoma. Ann Hematol 2009;88:921-2.